Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Spain to resume use of AstraZeneca's coronavirus vaccine on Wednesday

03/18/2021 | 02:25pm EST

MADRID, March 18 (Reuters) - Spain will resume administering AstraZeneca's coronavirus vaccine from next Wednesday, Health Minister Carolina Darias said on Thursday.

"The decision was taken unanimously as the benefits outweighed the risks, in line with the findings from the European Medicines Agency," Darias told a news briefing after a meeting with regional health chiefs on the subject.

Spain and about a dozen other countries had suspended the use of the shot earlier this week after reports of blood disorders, but the EU drugs regulator EMA said earlier on Thursday it was convinced the benefits of the vaccine were greater than the risks.

Spain, which aims to vaccinate 70% of its 47 million population by the end of the summer, has already given the first dose of the AstraZeneca vaccine to almost one million people out of a total of 7.68 million vaccines administered in Spain.

Early signs suggest the vaccination campaign is already helping to slow transmission, health officials have said, with the country's infection rate measured over the past two weeks now hovering around 128 cases per 100,000 people, down sharply for a peak of 900 in late January.

The Health Ministry added 6,216 cases on Thursday to its tally than now stands at 3.21 million, while the death toll rose by 117 to 72,910.

(Reporting by Jesús Aguado; editing by Andrei Khalip)


© Reuters 2021
All news about ASTRAZENECA PLC
11/30Oxford University Says Existing COVID-19 Vaccines Will Protect Against Omicron
MT
11/30Officials offer vaccine reassurance; WHO advises against travel bans
RE
11/30FTSE 100 marks worst month in over a year on Omicron hit
RE
11/30AstraZeneca's Lynparza Secures FDA Priority Review for BRCA-Mutated HER2-Negative High-..
MT
11/30ASTRAZENECA : Lynparza Gets FDA Priority Review -- Update
DJ
11/30Lynparza granted Priority Review in the US for BRCA-mutated HER2-negative high-risk ea..
AQ
11/30Genetron, AstraZeneca to Collaborate to Develop Solid Tumor Tests in China
MT
11/30LONDON STOCK EXCHANGE : Doubts over vaccine efficiency send FTSE 100 down
11/30Presidential Taskforce On Covid-19 Endorses Pfizer-BioNTtech Vaccine for 12+ Year Olds
AQ
11/30COVAX allocates 4.7 mln AstraZeneca COVID-19 vaccine doses to N.Korea
RE
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 919 M - -
Net income 2021 3 423 M - -
Net Debt 2021 25 253 M - -
P/E ratio 2021 37,4x
Yield 2021 2,56%
Capitalization 170 B 170 B -
EV / Sales 2021 5,45x
EV / Sales 2022 4,46x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 110,04 $
Average target price 137,59 $
Spread / Average Target 25,0%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC13.00%169 755
JOHNSON & JOHNSON1.16%420 557
ROCHE HOLDING AG15.70%334 662
PFIZER, INC.42.35%294 114
NOVO NORDISK A/S67.75%247 392
ELI LILLY AND COMPANY50.93%231 027